Preliminary results from FLAGSHP-1: A Phase I dose escalation study of ERAS-601, a potent SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors

被引：0
|
作者：
McKean, M. [1 ]
Barve, M. [2 ]
Hong, D. [3 ]
Parikh, A. [4 ]
Rosen, E. [5 ]
Yang, J. [6 ]
Picard, R. [6 ]
Yi, J. [6 ]
Brail, L. [6 ]
Vecchio, D. [6 ]
Meniawy, T. [7 ]
John, T. [8 ]
Wang, J. [9 ]
机构：
[1] Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA
[2] Mary Crowley Canc Res, Res Oncol, Dallas, TX USA
[3] MD Anderson, Invest Canc Therapeut ICT, Houston, TX USA
[4] Massachusetts Gen Hosp, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, Med, New York, NY USA
[6] Erasca Inc, San Diego, CA USA
[7] Linear Clin Res & Univ Western Australia, Med Oncol, Nedlands, WA, Australia
[8] Peter MacCallum Canc Ctr, Med Oncol, Melbourne, Australia
[9] Florida Cancers Specialists Sarah Cannon Res Inst, Drug Dev Unit, Sarasota, FL USA
来源：
EUROPEAN JOURNAL OF CANCER | 2022年 / 174卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
95
引用
收藏
页码：S34 / S34
页数：1
相关论文
共 50 条
  • [1] Preliminary dose escalation results of ERAS-601 in combination with cetuximab in FLAGSHP-1: a phase I study of ERAS-601, a potent and selective SHP2 inhibitor, in patients with previously treated advanced or metastatic solid tumors
    McKean, Meredith
    Rosen, Ezra
    Barve, Minal
    Meniawy, Tarek
    Wang, Judy
    Hong, David S.
    Yang, Jennifer
    Li, Zhengrong
    Picard, Roxana
    Brail, Les
    Vecchio, Daniela
    John, Thomas
    Cohen, Ezra
    Obara, Gregory
    Parikh, Aparna
    CANCER RESEARCH, 2023, 83 (08)
  • [2] Preliminary results from FLAGSHP-1: A phase 1 study of ERAS-601 as a monotherapy or in combination with cetuximab in patients (pts) previously treated for advanced chordoma.
    Gounder, Mrinal M.
    Rosen, Ezra
    Parikh, Aparna Raj
    Conley, Anthony Paul
    Hong, David S.
    Sheth, Siddharth
    Mai, Nicholas
    Sgroe, Erica
    Mitchell, Ryan
    Picard, Roxana
    Brail, Les H.
    Cote, Gregory Michael
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] A Phase I Dose-Escalation and Expansion Study of Telaglenastat in Patients with Advanced or Metastatic Solid Tumors
    Harding, James J.
    Telli, Melinda
    Munster, Pamela
    Voss, Martin H.
    Infante, Jeffrey R.
    DeMichele, Angela
    Dunphy, Mark
    Le, Mai H.
    Molineaux, Chris
    Orford, Keith
    Parlati, Frank
    Whiting, Sam H.
    Bennett, Mark K.
    Tannir, Nizar M.
    Meric-Bernstam, Funda
    CLINICAL CANCER RESEARCH, 2021, 27 (18) : 4994 - 5003
  • [4] Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.
    Brana, Irene
    Shapiro, Geoffrey
    Johnson, Melissa Lynne
    Yu, Helena Alexandra
    Robbrecht, Debbie
    Tan, Daniel Shao-Weng
    Siu, Lillian L.
    Minami, Hironobu
    Steeghs, Neeltje
    Hengelage, Thomas
    Tan, Eugene
    Biette, Kelly
    Xu, Kun
    Moody, Susan Elizabeth
    Jove, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] PF-06939999, a potent and selective PRMT5 inhibitor, in patients with advanced or metastatic solid tumors: A phase 1 dose escalation study.
    Ahnert, Jordi Rodon
    Perez, Cesar Augusto
    Wong, Kit Man
    Maitland, Michael L.
    Tsai, Frank
    Berlin, Jordan
    Liao, Kai Hsin
    Wang, I-Ming
    Markovtsova, Lada
    Jacobs, Ira A.
    Cavazos, Nora
    Li, Meng
    Tolcher, Anthony W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [6] Final results: A dose escalation phase I study of ARQ 197, a selective c-Met inhibitor, in patients with metastatic solid tumors
    Mekhail, T.
    Rich, T.
    Rosen, L.
    Chai, F.
    Semic-Suka, Z.
    Savage, R. E.
    Senzer, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] Capecitabine (Xeloda®) in combination with oxaliplatin:: a phase I, dose-escalation study in patients with advanced or metastatic solid tumors
    Díaz-Rubio, E
    Evans, TRJ
    Tabernero, J
    Cassidy, J
    Sastre, J
    Eatock, M
    Bisset, D
    Regueiro, P
    Baselga, J
    ANNALS OF ONCOLOGY, 2002, 13 (04) : 558 - 565
  • [8] Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Yamamoto, Noboru
    Tamura, Tomohide
    Yamamoto, Nobuyuki
    Yamada, Kazuhiko
    Yamada, Yasuhide
    Nokihara, Hiroshi
    Fujiwara, Yutaka
    Takahashi, Toshiaki
    Murakami, Haruyasu
    Boku, Narikazu
    Yamazaki, Kentaro
    Puchalski, Thomas A.
    Shin, Eisei
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (06) : 1165 - 1172
  • [9] Phase I, dose escalation and pharmacokinetic study of cediranib (RECENTIN™), a highly potent and selective VEGFR signaling inhibitor, in Japanese patients with advanced solid tumors
    Noboru Yamamoto
    Tomohide Tamura
    Nobuyuki Yamamoto
    Kazuhiko Yamada
    Yasuhide Yamada
    Hiroshi Nokihara
    Yutaka Fujiwara
    Toshiaki Takahashi
    Haruyasu Murakami
    Narikazu Boku
    Kentaro Yamazaki
    Thomas A. Puchalski
    Eisei Shin
    Cancer Chemotherapy and Pharmacology, 2009, 64 : 1165 - 1172
  • [10] Phase I dose-escalation study of E7080, a multikinase inhibitor, in patients with advanced solid tumors
    Nemunaitis, J. J.
    Senzer, N. N.
    Kurzrock, R.
    Ng, C. S.
    Das, A.
    Atienza, R. S.
    Zang, E. A.
    Jansen, M.
    Ashworth, S.
    Hong, D. S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345